New aggressive therapeutic options have recently become available to treat inflammatory arthritis (IA) and rheumatoid arthritis in particular. These treatments not only control joint destruction, they may also aid in new bone formation at sites of eroded bone. Separation of non-responders from responders to these treatments, is critical, and is known to lead to reduced disease burden, toxicity, side-effects and overall cost. The bones of the wrist are early targets of IA and are known to show response to therapy early. In this paper, we develop a method to quantify point-wise erosive changes of wrist bones in IA patients undergoing treatment. The method employs 3D registration-based morphometric analysis. Our results indicate that the proposed method has potential to improve sensitivity to small, early changes in bone erosion status. This study has potential to provide new imaging biomarkers to be used in clinical trials evaluating the efficacy of new arthritis drugs.